Source:http://linkedlifedata.com/resource/pubmed/id/16496338
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2006-4-3
|
| pubmed:abstractText |
Autoimmune hepatitis is classically a disease of young women. Our aims were to determine its occurrence, clinical phenotype, and outcome in elderly patients and contrast findings to young adults. Two-hundred-and-five white North American adults with definite type 1 autoimmune hepatitis were grouped according to age at presentation and the groups compared. Forty-seven patients (23%) were aged > or = 60 years (median age, 68 years), and 31 patients (15%) were aged < or = 30 years (median age, 25 years). The patients > or = 60 years had a higher frequency of cirrhosis at presentation than the patients < or = 30 years (33% versus 10%, P = .03). They also had thyroid or rheumatic diseases more commonly (42% vs. 13%, P = .006). HLA DR3 occurred more frequently in the patients < or = 30 years than in those > or = 60 years (58% vs. 23%, P = .004), and HLA DR4 occurred more often in the patients > or = 60 years (47% vs. 13%, P = .003). Patients aged > or = 60 years failed corticosteroid treatment less commonly than those aged < or = 30 years (5% vs. 24%, P = .03). Autoimmune hepatitis occurred in patients aged 18-30 years (15%), 31-39 years (15%), 40-49 years (21%), 50-59 years (25%), and > or = 60 years (23%). Differences in age distribution, HLA frequencies, and treatment outcome occurred after age > or = 40 years. In conclusion, elderly patients have a greater frequency of cirrhosis at presentation and HLA DR4 than patients < or = 30 years, and they have a lower occurrence of treatment failure. Transitions in clinical and genetic phenotypes occur after age > or = 40 years. Genetic susceptibilities may favor etiologic factors that are age-related.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0270-9139
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
43
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
532-8
|
| pubmed:meshHeading |
pubmed-meshheading:16496338-Adolescent,
pubmed-meshheading:16496338-Adult,
pubmed-meshheading:16496338-Age Distribution,
pubmed-meshheading:16496338-Age Factors,
pubmed-meshheading:16496338-Aged,
pubmed-meshheading:16496338-Aged, 80 and over,
pubmed-meshheading:16496338-European Continental Ancestry Group,
pubmed-meshheading:16496338-Female,
pubmed-meshheading:16496338-Genetic Predisposition to Disease,
pubmed-meshheading:16496338-HLA-DR3 Antigen,
pubmed-meshheading:16496338-HLA-DR4 Antigen,
pubmed-meshheading:16496338-Hepatitis, Autoimmune,
pubmed-meshheading:16496338-Humans,
pubmed-meshheading:16496338-Male,
pubmed-meshheading:16496338-Middle Aged,
pubmed-meshheading:16496338-Phenotype,
pubmed-meshheading:16496338-Retrospective Studies,
pubmed-meshheading:16496338-Treatment Outcome
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly.
|
| pubmed:affiliation |
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. czaja.albert@mayo.edu
|
| pubmed:publicationType |
Journal Article
|